X4 Pharmaceuticals Partners with Norgine for Mavorixafor Expansion

X4 Pharmaceuticals ( (XFOR) ) just unveiled an update.

X4 Pharmaceuticals has signed an exclusive licensing and supply agreement with Norgine to commercialize its product mavorixafor in Europe, Australia, and New Zealand. The deal, which includes an upfront payment of €28.5 million and potential milestone payments up to €226 million, allows Norgine to handle market access and commercialization, while X4 focuses on regulatory filings and the ongoing Phase 3 clinical trial. This strategic partnership aims to expand the availability of mavorixafor, a treatment for WHIM syndrome, to new territories and strengthen X4’s financial position.

More about X4 Pharmaceuticals

X4 Pharmaceuticals specializes in developing and commercializing therapies for rare immune system diseases, with a focus on CXCR4 receptor antagonists. The company is based in Boston, Massachusetts, and sells its product mavorixafor under the name XOLREMDI® in the U.S. It is currently conducting a Phase 3 clinical trial for certain chronic neutropenic disorders.

YTD Price Performance: -24.20%

Average Trading Volume: 3,500,979

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $97.23M

For an in-depth examination of XFOR stock, go to TipRanks’ Stock Analysis page.